These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 3078212)

  • 1. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
    Kant KS; Pollak VE; Dosekun A; Glas-Greenwalt P; Weiss MA; Glueck HI
    J Lab Clin Med; 1985 Jan; 105(1):77-88. PubMed ID: 3968467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
    J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of fibrinolytic and defibrinating agents in established experimental glomerulonephritis.
    Tipping PG; Thomson NM; Holdsworth SR
    Br J Exp Pathol; 1986 Aug; 67(4):481-91. PubMed ID: 3741774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.
    Mathieson PW; Thiru S; Peters DK; Oliveira DB
    Int J Exp Pathol; 1991 Dec; 72(6):679-93. PubMed ID: 1768613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
    Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
    Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrination with ancrod in glomerulonephritis: effects on clinical and histologic findings and on blood coagulation.
    Pollak VE; Glueck HI; Weiss MA; Lebron-Berges A; Miller MA
    Am J Nephrol; 1982; 2(4):195-207. PubMed ID: 6816068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
    Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
    Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects.
    Dosekun AK; Pollak VE; Glas-Greenwalt P; Kant KS; Penovich P; Lebron-Berges A; Weiss MA; Levinson JE
    Arch Intern Med; 1984 Jan; 144(1):37-42. PubMed ID: 6229228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors.
    Silva FG; Hoyer JR; Pirani CL
    Lab Invest; 1984 Oct; 51(4):404-15. PubMed ID: 6434880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
    Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
    Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ancrod causes rapid thrombolysis in patients with acute stroke.
    Pollak VE; Glas-Greenwalt P; Olinger CP; Wadhwa NK; Myre SA
    Am J Med Sci; 1990 May; 299(5):319-25. PubMed ID: 2186630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.
    Hariharan S; Pollak VE; Kant KS; Weiss MA; Wadhwa NK
    Clin Nephrol; 1990 Aug; 34(2):61-9. PubMed ID: 2225555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study.
    Lowe GD; Morrice JJ; Fulton A; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1978 Aug; 40(1):134-43. PubMed ID: 725844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary fibrin split products in lupus nephritis.
    Zizic TM; Cwazka WF; Young NS; Stevens MB
    J Rheumatol; 1976 Mar; 3(1):43-9. PubMed ID: 775087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic defibrinogenation by ancrod: effect on limb blood flow in peripheral vascular disease.
    Wiles PG; Nelson SR; Hampton KK; Casali B; Boothby M; Prentice CR
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):385-8. PubMed ID: 2133215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.